X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

    FDA Experts Recommend Changing COVID Jab Formulation In Fall

    FDA Continues To Deal With Issues With Expedited Clearance

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Test For Sterility of Cell Culture Using Ratio of NA To NAM

    Paxlovid Allowed By FDA To Sell At Certified Pharmacies

    Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

    GSK Unveils Its Transformation Through New Branding And Logo

    GSK To Aid 12 European Countries Prepare For Future Pandemic

    Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

    Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Merck and Orion Announce Global Collaboration for Oncology Drug

    Indian Government Launches Three MSMEs Pharma Programmes

    Indian Government Launches Three MSMEs Pharma Programmes

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

    Overall Coronavirus Monoclonal COVID-19 Variant Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

Content Team by Content Team
1st August 2022
in FDA Approvals, News
Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

Pfizer previously held out hope that Eucrisa would become the trendiest topical treatment for inflammatory skin conditions. However, the ointment never took off because of adverse reactions and funding problems. Arcutis Biotherapeutics, a young biotech company, is now introducing a novel medicine that addresses the same medication target but has a radically different product profile.

For the treatment of plaque psoriasis in patients 12 years of age and older, especially in skin folds called intertriginous regions, the cream medication roflumilast by Arcutis recently received FDA approval under the trade name Zoryve. The usage of the green light is unrestricted throughout the whole length of the sickness, from moderate to severe.

Following years of commercial planning, Arcutis will release the steroid-free Zoryve cream as soon as it gets approval, CEO Frank Watanabe confirmed.

Watanabe criticised the overly aggressive pricing of current topicals and stated Arcutis will charge $825 for each 60g tube of Zoryve. That is significantly less expensive than the $1,325 list price per tube Dermavant has set for its recently FDA-approved rival psoriasis ointment Vtama or the $1,950 sticker Incyte placed on its topical atopic dermatitis medication Opzelura.

According to Watanabe, Arcutis chose that amount because insurance providers felt it was an acceptable fee that they would be prepared to reimburse without too many barriers and limitations. The company believes they will be able to get comprehensive and heavy coverage because of this.

Pfizer decided not give Eucrisa a different line of sales report in 2021 despite initial estimates that it may reach peak sales of over $2 billion. Its commercial failure is partly due to unfavourable formulary positioning and greater rebates in the face of inexpensive steroids. According to Mizuho analysts, Arcutis has estimated that the combined sales potential for topical roflumilast across a number of indications will range from $1.8 billion to $3.8 billion in 2030. The PDE4 inhibitor class includes both Eucrisa and Zoryve, but Watanabe believes they are two totally different drugs.

First off, Eucrisa, which is only now licenced for eczema, has never been effective for psoriasis. Early safety testing on a greater ratio of the medication failed for psoriasis, so Watanabe recalled that the drug’s original inventor, Anacor Pharma—which Pfizer acquired for $5.2 billion in 2016—lowered the dosage and switched to eczema.

Eucrisa still has a scorching or stinging feeling even in its present form, which has massively diminished its uptake.

Otezla, an oral PDE4 inhibitor manufactured by Amgen, has 2021 sales of $2.2 billion. However, in clinical studies for plaque psoriasis, Otezla could have a 17% adverse effect rate for both diarrhoea and nausea. According to Watanabe, Zoryve has psoriasis efficacy that is at least as excellent as Otezla’s, without the stinging and burning of Eucrisa and with barely any of Otezla’s gastrointestinal disorders.

In the DERMIS-1 and DERMIS-2 clinical studies, 40% of patients who received Zoryve reported a successful course of treatment by week 8, compared to 6 to 7% of patients who received a placebo.

The FDA has raised safety issues for JAK inhibitors, particularly Opzelura, and SVB Securities analysts lately observed that doctors greatly enjoy Zoryve’s robust safety profile. In a poll conducted by SVB last year, 84% of doctors said they had no concerns about Zoryve’s safety profile, and 45% of them thought it was promising.

Additionally, whereas Eucrisa and Otezla must be consumed twice daily, Zoryve only needs to be taken once daily. Watanabe pointed out that another reason Eucrisa failed to win over patients was its oily ointment texture, whereas Zoryve’s cream composition allows for rapid skin absorption. In the present psoriasis treatment landscape, innovative biologics including Cosentyx by Novartis, Taltz by Eli Lilly, and Skyrizi by AbbVie have shown impressive success in treating psoriasis. Watanabe, who formerly assisted Amgen with the marketing of Enbrel, claimed that Zoryve is not portrayed as a rival to biologic medications.

The chief executive stated that they really regard themselves as being comparable to—not competing with—the biologics. Watanabe observed that despite biologics’ outstanding performance, only 8% of psoriasis patients actually take them, with practically all of them using topical medications. In addition, biologics have demonstrated their ability to restore totally normal skin in roughly 50% of psoriasis patients. He continued, that leaves an additional 50% where Zoryve could assist in wiping away any leftover plaques.

With a specific mention of healing skin creases on its label, Zoryve distinguishes itself further. These are delicate areas where using conventional steroids can result in more negative effects. Doctors advised us to utilise Zoryve there first because it was so clear and there were not any other viable solutions, according to Watanabe.

The initial users of Zoryve will probably be other individuals who have used steroids and Vitamin D analogues repeatedly, those who have itching, and those who are allergic to steroids, according to Watanabe.

However, Dermavant’s Vtama cream, an AhR agonist, may pose a significant threat to Zoryve as it too has a relatively good safety profile, with the exception of instances of hair follicle irritation. Physician replies to SVB’s poll on Vtama’s efficacy, safety, and potential use were all more positive than those for Zoryve.

Arcutis has spent a lot of time getting ready for the launch. The company’s payer team was hired a year ago, and its medical affairs team has been teaching doctors for a year and a half. Additionally, it has employed 50% of its sales crew, with the remaining hiring to be approved.

The business is also moving beyond psoriasis. By the end of the year, results from Zoryve’s phase 3 atopic dermatitis trials should be available. Arcutis now aims to register with the FDA beginning next year after a phase 3 test on a foam variant of the medication reportedly produced promising findings, according to Watanabe.

Previous Post

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
FDA Approvals

FDA Continues To Deal With Issues With Expedited Clearance

1st August 2022
Test For Sterility of Cell Culture Using Ratio of NA To NAM
Drug Development

Test For Sterility of Cell Culture Using Ratio of NA To NAM

1st August 2022
Authorities Agree To Work Together Towards Integrating RWE
IPR Data Management

Authorities Agree To Work Together Towards Integrating RWE

1st August 2022
NHS Lays Long COVID Action Plan For Many With Chronic Signs
Facilities & Operation

NHS Lays Long COVID Action Plan For Many With Chronic Signs

30th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Drug Development

Pfizer Has Long-Term Plans For Paxlovid, Comirnaty, COVID-19

30th July 2022
GSK Unveils Its Transformation Through New Branding And Logo
News

GSK To Aid 12 European Countries Prepare For Future Pandemic

29th July 2022

Latest News

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream
FDA Approvals

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

1st August 2022
BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology
Press Statements

BioMed X Institute and Healthcare Business of Merck KGaA, Darmstadt, Germany, Start New Research Project in Oncology

1st August 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
FDA Approvals

FDA Continues To Deal With Issues With Expedited Clearance

1st August 2022
Test For Sterility of Cell Culture Using Ratio of NA To NAM
Drug Development

Test For Sterility of Cell Culture Using Ratio of NA To NAM

1st August 2022
Authorities Agree To Work Together Towards Integrating RWE
IPR Data Management

Authorities Agree To Work Together Towards Integrating RWE

1st August 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In